18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study-Reference-Cited by-同舟云学术

18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study

Published:2018-04-20 Issue:2 Volume:139 Page:399-409
ISSN:0167-594X
Container-title:Journal of Neuro-Oncology
language:en
Short-container-title:J Neurooncol

Author:

Patel Chirag B.,Fazzari Elisa,Chakhoyan Ararat,Yao Jingwen,Raymond Catalina,Nguyen Huytram,Manoukian Jasmine,Nguyen Nhung,Pope Whitney,Cloughesy Timothy F.,Nghiemphu Phioanh L.,Czernin Johannes,Lai Albert,Ellingson Benjamin M.^ORCID

Funder

National Institute of Neurological Disorders and Stroke

American Medical Association Foundation

American Cancer Society

American Brain Tumor Association

National Brain Tumor Society

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Neurology (clinical),Neurology,Oncology

Link

http://link.springer.com/article/10.1007/s11060-018-2877-6/fulltext.html

Reference40 articles.

1. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol 17(Suppl 4):iv1–iv62

2. Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z (2015) Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314:2535–2543

3. Chinot OL, Nishikawa R, Mason W, Henriksson R, Saran F, Cloughesy T, Garcia J, Revil C, Abrey L, Wick W (2016) Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. Neuro Oncol 18:1313–1318

4. Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran DD, Brem S, Hottinger AF, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Burna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318:2306–2316

5. Ellingson BM, Wen PY, Cloughesy TF (2018) Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma. Neuro Oncol 20(4):457–471

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of [18 F]FDOPA PET as an adjunct to conventional MRI in the diagnosis of aggressive glial lesions;European Journal of Nuclear Medicine and Molecular Imaging;2024-04-19

2. The role of [18F]fluorodopa positron emission tomography in grading of gliomas;Journal of Neuro-Oncology;2022-11-24

3. PET radiotracers in glioma: a review of clinical indications and evidence;Clinical and Translational Imaging;2022-08-27

4. Nuclear medicine and radiotherapy in the clinical management of glioblastoma patients;Clinical and Translational Imaging;2022-05-05

5. What Does PET Imaging Bring to Neuro-Oncology in 2022? A Review;Cancers;2022-02-10